Last reviewed · How we verify
Grifulvin V (GRISEOFULVIN)
Grifulvin V (GRISEOFULVIN) is a small molecule tubulin inhibiting agent developed by WYETH AYERST and currently owned by Johnson and Johnson. It targets the solute carrier family 22 member 1 and was FDA approved in 1962 for the treatment of various fungal infections, including onychomycosis, tinea barbae, tinea capitis, tinea corporis, tinea cruris, and tinea pedis. Grifulvin V is available as a generic medication due to its off-patent status. Key safety considerations include potential gastrointestinal side effects and interactions with other medications. It has a bioavailability of 48%.
At a glance
| Generic name | GRISEOFULVIN |
|---|---|
| Sponsor | Johnson And Johnson |
| Drug class | Tubulin Inhibiting Agent [EPC] |
| Target | Solute carrier family 22 member 1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1962 |
Approved indications
- Onychomycosis due to dermatophyte
- Tinea barbae
- Tinea capitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
- Skin rashes
- Urticaria
- Angioneurotic edema
- Erythema multiforme-like drug reaction
- Paresthesias
- Oral thrush
- Nausea
- Vomiting
- Epigastric distress
- Diarrhea
- Headache
- Fatigue
Drug interactions
- levonorgestrel
- mestranol
- norelgestromin
- norethisterone
- norethynodrel
- norgestimate
- warfarin
Key clinical trials
- Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions (PHASE1)
- Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (PHASE3)
- Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH (PHASE1)
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions (PHASE1)
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions (PHASE1)
- Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) (NA)
- Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Grifulvin V CI brief — competitive landscape report
- Grifulvin V updates RSS · CI watch RSS
- Johnson And Johnson portfolio CI